Cover

Immune-Mediated Neuromuscular Diseases

Editor(s): Pourmand R. (Stony Brook, N.Y.) 
Table of Contents
Vol. 26, No. , 2009
Section title: Paper
Pourmand R (ed): Immune-Mediated Neuromuscular Diseases. Front Neurol Neurosci. Basel, Karger, 2009, vol 26, pp 26–66
(DOI:10.1159/000212368)

Nonsystemic Vasculitic Neuropathy: Update on Diagnosis, Classification, Pathogenesis, and Treatment

Collins M.P. · Periquet-Collins I.
Neurology Department, Medical College of Wisconsin, Milwaukee, Wisc., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 4/6/2009
Cover Date: 2009

Number of Print Pages: 41
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9141-6 (Print)
eISBN: 978-3-8055-9142-3 (Online)

Abstract

The primary systemic vasculitides are autoimmune disorders characterized by chronic immune responses directed against vascular structures. They commonly affect small or medium-sized vessels in the peripheral nervous system (PNS), producing vasculitic neuropathies. Some patients develop vasculitis clinically restricted to the PNS, known as nonsystemic vasculitic neuropathy (NSVN), the most commonly encountered vasculitic neuropathy in pathologically based series. Diabetic and nondiabetic radiculoplexus neuropathies are clinical variants of NSVN. NSVN is clinically similar to systemic vasculitis-associated neuropathies except for reduced severity. Patients most commonly present with progressive, stepwise pain, weakness, and numbness over multiple months. Almost all exhibit a multifocal or asymmetric, distally accentuated pattern of involvement. The most commonly affected nerves are the common peroneal nerve in the leg and the ulnar nerve in the arm. Sedimentation rate is mildly to moderately elevated in 50%; other markers of systemic inflammation are generally normal. Electrodiagnostic studies reveal a predominantly axonal, asymmetric, sensorimotor polyneuropathy, but pseudo-conduction blocks may occur. Definite diagnosis requires biopsy evidence of vascular inflammation and signs of active or remote vascular damage. In biopsies lacking definite vasculitis, the diagnosis is suspected if axonal alterations are accompanied by perivascular inflammation and such supportive features as Wallerian-like degeneration, asymmetric fiber loss, hemosiderin, vascular immune deposits, neovascularization, myofiber necrosis/regeneration, focal perineurial damage, and endoneurial purpura. NSVN preferentially affects larger epineurial arterioles. Epineurial infiltrates are composed primarily of T cells and macrophages, suggesting that cellular cytotoxicity is the primary effector mechanism. Systemic vasculitides with progressive neuropathy are usually treated with cyclophosphamide and prednisone. No randomized controlled trial of therapy has been performed in NSVN, but data from retrospective cohorts suggest that combination therapy is more effective than steroid monotherapy. Once remission has been induced, cyclophosphamide should be replaced with azathioprine or methotrexate. Refractory patients can be treated with intravenous immunoglobulin, mycophenolate, rituximab, infliximab, or alemtuzumab. Although long-term outcome is reasonably good, more than one third of patients relapse, infrequent patients die from the disease or its treatment, and still others develop chronic pain.


  

Author Contacts

Michael P. Collins, MD, Neurology Department, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226 (USA), Tel. +1 414 805 5203, Fax +1 414 256 0469, E-Mail mcollins@mcw.edu

  

Article Information

Published online: April 06, 2009
Number of Print Pages : 41

  

Publication Details

Book Serie: Frontiers of Neurology and Neuroscience, Vol. 26, Year 2009

Editor(s): Bogousslavsky, J. (Montreux)
ISSN: 1660-4431 (Print), eISSN: 1662-2804 (Online)

For additional information:
http://content.karger.com/ProdukteDB/produkte.asp?issn=1660-4431

Book Title: Immune-Mediated Neuromuscular Diseases

Editor(s): Pourmand R (ed)

For additional information:
http://content.karger.com/ProdukteDB/produkte.asp?issn=1660-4431&volume=26


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 4/6/2009
Cover Date: 2009

Number of Print Pages: 41
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9141-6 (Print)
eISBN: 978-3-8055-9142-3 (Online)


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.